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Abstract 
Over the past years, it has become evident that cancer initiation and progression depends on several 
components of the tumor microenvironment, including inflammatory and immune cells, fibroblasts, 
endothelial cells, adipocytes, and extracellular matrix. These components of the tumor 
microenvironment and the neoplastic cells interact with each other providing pro and antitumor 
signals. The tumor-stroma communication occurs directly between cells or via a variety of 
molecules secreted, such as growth factors, cytokines, chemokines and microRNAs. This 
secretome, which derives not only from tumor cells but also from cancer-associated stromal cells, 
is an important source of key regulators of the tumorigenic process. Their screening and 
characterization could provide useful biomarkers to improve cancer diagnosis, prognosis, and 
monitoring of treatment responses. 
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Introduction 
The secretome consists of a subset of proteins 
and metabolites released by a cell, tissue or an 
organism, which plays an important role in the 
regulation of cell-to-cell interactions essential to their 
normal physiological functions. Secretome alterations 
are often associated with atypical cellular phenotypes 
that are indicative of diseases such as cancer. 
Secretome analysis has identified biomarkers for 
different pathological conditions including chronic 
inflammation, neurodegenerative disorders, cancer, 
cardiovascular disease, and diabetes. Moreover, 
secretome studies have contributed to better 
understand the molecular mechanisms involved in 
the pathogenesis of several diseases and to the 
development of novel treatment strategies [1, 2]. 
Specifically, mutations that underlie cancer 
progression can lead to altered protein expression 
patterns, which can be detected in serum and other 
body fluids allowing for early diagnosis and 
prediction to treatment response [3]. 
The Secretome 
The term secretome was first used in a study by 
Tjalsma et al. in the year of 2000 [4] to designate the 
whole secretory processes in the bacteria Bacillus 
subtilis. The definition of secretome was later 
expanded to denote the global group of proteins 
secreted, released or detached into the extracellular 
space by a cell, tissue, organ or organism at any given 
time [5]. Such proteins comprise a large variety of 
bioactive molecules that play important roles in 








interactions. They may act in an autocrine or 
paracrine fashion, positively or negatively influencing 
the ability of cells to survive, proliferate and 
differentiate [6].  
Proteins secreted via the classical pathway, are 
synthesized in the endoplasmic reticulum (ER) 
presenting a signal peptide at their N-terminus [7]. 
They are transported to the Golgi apparatus in a coat 
protein complex II (COPII)-coated vesicles and then, 
within secretory vesicles, to the plasma membrane 
and cell exterior [8, 9]. During their passage through 
the Golgi apparatus, proteins are modified by 
different processes such as glycosylation [10], 
phosphorylation [11] and palmitoylation [12, 13]. 
Proteins can also be exported by the 
non-classical pathway via Golgi-independent 
mechanisms. This pathway corresponds to the 
translocation of proteins from the cytoplasm directly 
across the plasma membrane into the extracellular 
compartment. Examples include the fibroblast growth 
factor 2 (FGF2) and cytokines involved in 
inflammation and angiogenesis [14]. The non-classical 
pathway uses vesicular and non-vesicular transport 
mechanisms. The non-vesicular mechanisms 
encompass self-sustained protein translocation 
through plasma membranes and ABC 
transporter-mediated secretion. The vesicular 
mechanism depends on intermediate carriers such as 
endosomes, multivesicular bodies (MVBs), 
autophagosomes and secretory lysosomes that fuse to 
the plasma membrane to release their contents 
directly to the cell exterior or in a 
vesicular/exosome-dependent manner [15, 16]. 
Secreted proteins are involved in a variety of 
physiological processes like immune response, blood 
coagulation, digestion, cell signaling and cell 
communication, and include hormones, proteases and 
digestive enzymes, immunoregulatory 
cytokines/chemokines and growth factors [17]. 
Non-protein compounds, such as DNAs, RNAs, and 
lipids, as well as proteins, can be exported by 
exosomes [1, 18, 19] and mediate important 
intercellular signaling pathways [20], which may 
influence local and even distant microenvironments 
[21]. 
In addition to participating in many normal 
physiological processes, secretome components are 
involved in the pathogenesis of several diseases, such 
as cancer, and may promote invasion of the 
surrounding tissues, evasion of immune defenses and 
distant organ colonization [6]. Therefore, a better 
understanding of the mechanisms regulating the 
secretome can lead to the development of novel 
targeted therapies. 
Secretome in Cancer 
For many years, cancer was considered a 
stand-alone cell process. The concept was focused on 
genetically transformed cells and their progression to 
a malignant condition [22]. However, it is becoming 
clear that cancer cells do not act isolated during their 
progression to malignancy. The primary tumor cells 
recruit and activate non-transformed stromal cells, 
including fibroblasts, endothelial, inflammatory and 
immune system cells [22, 23], in order to promote a 
microenvironment favorable to disease progression 
[1, 22]. Besides stromal cells, the tumor 
microenvironment contains the extracellular matrix 
(ECM), which is rich in collagens, proteoglycans, 
hyaluronic acid, laminins and fibronectin [24], and 
provides the support structure that facilitates tumor 
proliferation and dissemination. This non-cellular 
macromolecular structure functions therefore as a 
scaffold for tumor tissue organization and contributes 
to the network of cell interactions mediated by surface 
receptors and embedded signaling molecules [23]. 
The tumor-stroma communication occurs 
directly between cells and, as cited above, via a 
variety of molecules secreted, such as growth factors, 
cytokines, chemokines and microRNAs [25, 26]. 
Biochemical events may also arise from the 
mechanical properties and physical signals of the 
microenvironment, including contractile forces and 
matrix stiffness [27]. The heterotypic secretome, 
which derives not only from tumor cells but also from 
cancer-associated stromal cells, is an important source 
of markers and key regulators of the tumorigenic 
process [28, 29]. The tumor microenvironment is 
therefore much broader than the central unit formed 
by the neoplasm. Its complexity is due to the resident 
or recruited elements and multidirectional and 
dynamic interactions between them, which end up 
generating a loss of the normal tissues architecture, 
sites of inflammation, hypoxia and consequently 
neoangiogenesis to contemplate the high needs for 
oxygen and nutrients [1, 29].  
Alterations of secretome composition during 
tumor development and progression depend on 
genetic mutations and nonmutational changes that 
affect gene expression. For example, high expression 
of the transcriptional activator c-MYC can result in 
altered levels of several secreted factors associated 
with cell proliferation, such as transforming growth 
factor beta-2 (TGF-beta-2). Target genes activated by a 
mutant tumor suppressor protein p53 also code 
secreted factors that may increase invasion of cancer 
cells. Likewise, loss of another tumor suppressor 
protein, the phosphotidyl-inositol phosphatase 
(PTEN), induces a more aggressive secretome that has 
been linked to tumor invasion and metastasis (for 




references, see [1]). Hawkins and collaborators [30] 
recently reported that activation of Wnt signaling in 
Ewing sarcoma cells results in an enrichment of 
secreted proteins involved in ECM composition, 
organization and degradation, potentially affecting 
the crosstalk between cancer cells and their 
microenvironment and therefore impacting tumor 
progression. 
The data above paint a picture where neoplastic 
cells acquire mutations and secrete factors aiming to 
create, in a figurative sense, a scene with actors and 
scenery working to benefit the tumor, which means 
survival, proliferation, invasion and metastasis. The 
outcome, if positive or negative for the host, will be 
driven by classical natural selection influenced by the 
initial conditions, both constitutive and 
micro-/macro-environmental, and their interactions. 
Strategies to direct or even control this Darwinian 
character of cancer focusing on neoplastic cells and 
their habitat may overcome current therapeutic 
limitations, as previously discussed by Greaves and 
Maley [31]. 
The crosstalk between neoplastic and 
stromal cells 
An early step in cancer progression is the 
epithelial-mesenchymal transition (EMT), a cellular 
process characterized by changing from epithelial to a 
mesenchymal phenotype, which increases the 
capacity of migration, invasion, and apoptosis 
resistance. This process also occurs during 
embryogenesis and in tissue regeneration after injury, 
the latter usually associated with inflammation [32]. 
During the neoplastic process, remodeling of the 
extracellular matrix follows epithelial-mesenchymal 
transition. Analysis of the cell secretome at this stage 
has shown increased expression of proteases, ECM 
components, factors that promote migration and 
reduced expression of adhesion proteins [33, 34]. The 
secretome of non-transformed cells with sustained 
expression of c-Myc also modulate the 
composition/function of ECM and basement 
membrane and show high ability to induce 
proliferation, overcome senescence, and to attract 
fibroblasts. Alterations of matrix components can be 
seen as an event that is able to interrupt normal tissue 
organization. Moreover, the ability to attract 
fibroblasts suggests that the secretome can change the 
crosstalk between epithelial and stromal cells in early 
stages of tumorigenesis [6].  
Fibroblasts represent the most abundant cells of 
the tumor stroma and play a critical role in tumor 
growth, survival, proliferation, migration, invasion, 
and metastasis [35, 36]. Under normal conditions, the 
fibroblasts are quiescent and are activated during 
tissue regeneration after injury, originating 
myofibroblasts. In the tumor microenvironment, 
fibroblast activation is induced by stimuli derived 
from neoplastic cells or immune system cells, 
particularly growth factors and interleukins, which 
lead to changes in its morphology and function [37]. It 
also seems to be self-induced by mutations leading to 
loss of the members of the tissue inhibitor of 
metalloproteinases (TIMP) gene family, which are 
associated with the control of the extracellular matrix 
through direct inhibition of metalloproteinases [38]. 
The activated fibroblasts are often called 
cancer-associated fibroblasts (CAFs) and comprise a 
heterogeneous cell population identified by a number 
of markers, including the alpha-smooth muscle actin 
(alpha-SMA) protein [39]. This protein is also present 
in resident fibroblasts and myofibroblasts [40, 41]. 
CAFs may originate from different resident 
precursors such as fibroblasts chronically exposed to 
oxidative stress [42] or from senescent cells with 
profiles similar to the senescence-associated secretory 
phenotype [43]. Bone marrow–derived mesenchymal 
stem cells (BMSCs) can also differentiate in CAFs. 
This conclusion is based on the observation that colon 
cancer cells stimulate differentiation of BMSCs to a 
CAFs-like phenotype with increased expression of 
alpha-SMA and vimentin. Importantly, it was also 
observed that Notch signaling mediates 
transformation of BMSCs to CAFs through the 
downstream TGF-beta/Smad signaling pathway [44]. 
The cytokine TGF-beta is secreted in a latent form [45] 
that upon activation becomes a potent inducer of 
epithelial-mesenchymal transition [46]. Mesenchymal 
cells with chromosomal abnormalities similar to those 
found in adjacent epithelial cancer cells express 
alpha-SMA and vimentin and do not express keratin 
[47]. These findings suggest that CAFs can also be 
directly derived from neoplastic cells that have 
undergone epithelial-mesenchymal transition by 
TGF-beta induction. Other cytokines participate in 
fibroblast activation including the interleukin 6 (IL-6) 
that reduces the expression of the tumor suppressor 
proteins p16INK4A, p21, and p53 in fibroblasts. IL-6 acts 
on the Jak2/STAT3 pathway through negative control 
of AUF1 (hnRNP D0) and promotes the expression of 
myofibroblast markers such as alpha-SMA [48]. 
CAFs constitute a heterogeneous population 
with a divergent transcriptome and secretome. In oral 
carcinomas, Costea and collaborators identified two 
distinct CAF subtypes: one with transcriptome and 
secretome similar to normal fibroblasts, high number 
of motile cells and cells responsive to TGF-beta; and 
another subtype with a dissimilar transcriptome, few 
motile cells and a high secretion of TGF-beta [49]. This 
heterogeneity suggests the existence of a 




subpopulation of stationary/low migratory 
fibroblasts responsible for the synthesis of various 
growth factors, cytokines and matrix 
metalloproteinases (MMPs) [49], which may be 
activated by signals emanating from neoplastic cells 
[50, 51]. Indeed, several studies on cancer-derived 
myofibroblast secretome observed an increase in the 
production and activation of MMP-1, -2, and -3, which 
may contribute to the remodeling of the cancer cell 
microenvironment and therefore to cell migration 
[52], as well as proteins associated with invasion and 
metastasis, or that act in the protection of cells against 
injuries caused by reactive oxygen species [38, 53]. 
Contrary to their role in neoplastic progression, the 
signals derived from normal fibroblasts and CAFs can 
inhibit proliferation of colon cancer cells, as reported 
by Chen and collaborators [54]. Similarly, the Tanaka 
group showed that CAFs induce apoptosis in gastric 
carcinoma cells, preventing proliferation-dependent 
invasion and suggesting a protective effect against 
cancer. However, the authors also observed that 
extracellular vesicles released by apoptotic cells 
activate fibroblasts and promote cancer invasion led 
by CAFs and tumor dissemination [55]. Therefore, 
fibroblasts may exhibit tumor suppressive or 
pro-tumorigenic activities and, unfortunately, no 
specific marker is known to be effective in stratifying 
their subsets of phenotypes [56]. From the data 
presented above, it is apparent that CAFs are an 
important stromal element that works in favor of but 
also against tumor development and progression 
through many factors released by these cells (Figure 
1). Other stromal cells exhibit similar responses, such 
as macrophages and neutrophils, as will be discussed 
in the next sections. 
Growing evidence from the literature has 
suggested that cancer stem cells (CSCs) or 
tumor-initiating cells show resistance to 
chemotherapeutic agents [57, 58]. Su and 
collaborators recently demonstrated that this feature 
is supported by a subset of CAFs with high expression 
of the cell-surface molecules CD10 and GPR77. 
CD10+GPR77+ CAFs are insensitive to chemotherapy 
and associated with shorter survival in different 
cancer types. Moreover, they can promote the 
formation of a supporting niche for CSCs and induce 
chemoresistance in CSC by secreting 
pro-inflammatory interleukins IL-6 and IL-8, a 
function dependent of a persistent activation of the 
nuclear transcription factor kappa B (NF-kB) [59]. 
These findings are of particular importance for the 
development of new approaches for diagnosis, 
prognosis, and monitoring treatment response in 
tumors driven by CSCs. 
 
Figure 1. The crosstalk between neoplastic cells and cancer-associated fibroblasts (CAFs). Neoplastic cells induce stationary CAFs to synthesize cytokines, matrix 
metalloproteinases (MMPs), and growth factors (GFs), such as TGF-beta, leading to proliferation, migration, invasion and metastasis. Motile CAFs can be derived from neoplastic 
cells that have undergone epithelial-mesenchymal transition (EMT) by TGF-beta induction. CAFs may exhibit tumor suppressive activities inducing apoptosis and preventing 
proliferation.  




The role microenvironment as a key player in the 
development of chemoresistance has recently been 
analyzed by the Dzobo group [60], with special 
attention to mesenchymal stem cells, fibroblasts, 
macrophages, cancer stem cells, and EMC 
components. The authors highlighted the fact that an 
abnormal ECM composition rich in collagen activates 
signaling cascades such as the MEK-ERK pathway, 
which induces proliferation, survival, or even 
apoptosis. High expression of collagen also increases 
ECM stiffness, providing a physical barrier that 
reduces blood flow and drug delivery. In addition, the 
acidic character of this extracellular environment due 
to lactate accumulation generated by the high 
glycolytic rate of tumor cells facilitates drug 
inactivation - another step of the chemoresistance 
process [60].  
Molecules in the tumor microenvironment 
derived from cancer or stromal cells, therefore, 
modulate biological processes that drive malignant 
progression, tumor response to drugs and the 
development of chemoresistance. In other words, 
metabolic pathways of cancer cells depend on their 
microenvironment components and also on the level 
of these components. Muir and Vander Heiden 
reported a number of examples showing the 
differences of drug response between tumor cells in 
vivo and cells in culture, which are due to differences 
in nutrients levels between tissues and standard 
culture medium [61]. Understanding how the 
nutrients change metabolism is crucial for the 
development of new therapies and to identify efficient 
approaches for subsets of cancer patients carrying 
specific constitutive or somatic mutations. 
Senescence-Associated Secretome and 
Cancer 
Senescence is a defense mechanism that has a 
great impact on the ability of cells to communicate, 
regardless of the cell type and source of the signal. 
This mechanism is a response to stress, which blocks 
cell proliferation and is often associated with 
expression of the tumor suppressor protein p16INK4a 
and accompanied by a secretory phenotype 
(senescence-associated secretory phenotype - SASP) 
with stress-type–dependent profile [62-64]. Cells in a 
senescent state and driven by NF-kB secrete 40-80 
bioactive molecules, including pro-inflammatory 
interleukins and chemokines, growth and angiogenic 
factors, metalloproteinases and components of ECM, 
which act in a paracrine manner and can have both 
beneficial and detrimental effects [65-68]. In fact, 
senescence may be seen as a cancer suppressor 
mechanism, with the 
inflammatory SASP phenotype 
inducing immune cells to 
modulate tissue regeneration 
and senescent cell removal, 
and secreting pro-senescent, 
pro-apoptotic and 
anti-angiogenic factors 
(reviewed by [69]). However, 
the secretome of these cells 
also include factors that induce 
proliferation of premalignant 
cells in vitro and in vivo [70, 71] 
and stimulate migration and 
invasion of pre-neoplastic and 
endothelial cells (Figure 2). In 
addition, these factors [66, 72] 
may promote the formation of 
tumors in vivo and confer 
metastatic properties [73, 74].  
As suggested by 
Muñoz-Espín D et al [75] and 
Storer M et al [76], senescence 
is a normal programmed 
mechanism, which operates 
similarly to apoptosis to 
remove cells at risk of 
abnormal cell growth. It is 
found in embryonic tissue 
 
Figure 2. Senescence-associated secretome. Senescence-associated microenvironment is rich in matrix 
metalloproteinases (MMPs), cytokines, growth and angiogenic factors. Senescent cells may secrete pro-senescent, 
pro-apoptotic and anti-angiogenic factors, as well signals to induce immune cells to modulate tissue regeneration and 
senescent cell removal. 




remodeling and was probably adapted during 
evolution to act in tissue regeneration in the adult 
organism. A downside of this response is that the 
clearance of senescent cells can also remove 
non-senescent cells. Moreover, the number of 
senescent cells increases with age and the immune 
system may not be able to remove them completely, 
which can lead to a rich senescence-associated 
microenvironment with cytokines, growth and 
angiogenic factors, increasing the risk of malignant 
transformation [77]. The physiological relevance and 
the consequences of senescence were evaluated by 
Baker et al [78], who observed that induction of 
apoptosis in p16INK4A-positive senescent cells extends 
lifespan, has a tumor-protective effect, and attenuates 
age-related deterioration of several organs. 
Differently, Takasugi and collaborators reported 
evidences of the relationship between senescence- 
associated secretome and tumorigenesis. The authors 
observed that exosome-like small extracellular 
vesicles (sEVs) secreted by senescent cells are 
enriched in receptor tyrosine kinase EphA, an 
expression event regulated by reactive oxygen species 
(ROS) levels. After the ephrin ligand binding, EphA 
can activate Erk pathway and mediate proliferative 
effects [79]. 
The literature has shown that oxidative stress 
and chemotherapeutic drugs promote senescence in 
sensitive neoplastic cells, and the formation of a 
proinflammatory and protumoral senescence- 
associated secretome driven by a poly(ADP-ribose) 
polymerase-1 (PARP-1) and NF-kB signaling. These 
data make plausible the hypothesis that a senescent 
phenotype induced by ROS and DNA damage may 
stimulate neighbor resistant cells to proliferate and 
invade surrounding tissues, ensuring tumor survival 
[74]. This idea again evokes natural selection forces 
and the need to combine different drugs to target 
different cells within the neoplastic population. 
The Inflammatory Secretome and Cancer  
It is estimated that 25% of cancers are 
inflammation-related cancers [80]. The first 
observations on this association were carried out by 
the German physician Rudolf Virchow in the 19th 
century, when he described that leukocyte infiltration 
in tumors is linked to immune responses [81]. Today it 
is widely recognized that inflammation promotes 
carcinogenesis. The hallmarks of cancer proposed by 
Hanahan and Weinberg in 2011 [82] currently include 
two features that take into account inflammation: 
inflammatory environment and evasion of immune 
attack. 
There are several examples of chronic 
inflammation that increase the risk of developing 
cancer. These include the predisposition of patients 
with Crohn's disease to colorectal cancer [83], 
Helicobacter pylori infection to gastric cancer [84], and 
human papillomavirus (HPV) infection to cervical 
cancer [85] and head and neck carcinoma [86, 87]. 
Similarly, non-steroidal anti-inflammatory drugs 
decrease the risk of cancer death in various tumor 
types [88, 89].  
The inflammatory processes may contribute to 
multiple stages of tumor development through 
growth factors, survival factors, proangiogenic 
factors, signals that activate EMT, enzymes that 
modify the extracellular matrix and facilitate invasion 
and metastasis, as well as reactive oxygen species that 
are actively mutagenic and promote neoplastic 
progression [82]. 
According to Mantovani et al [80], the 
inflammation-cancer relationship may be interpreted 
as having two pathways: the extrinsic pathway, 
initiated by inflammation caused by external agents, 
and the intrinsic pathway initiated by mutations or 
epigenetic changes in oncogenes and tumor 
suppressors, which induce the expression of 
inflammation-related programs. These two pathways 
activate transcription factors, such as NF-kB, signal 
transducer and activator of transcription 3 (STAT3) 
and hypoxia-inducible factor 1-alpha (HIF1-alpha). 
The resulting signaling events activate leukocytes to 
produce inflammatory mediators, including 
cytokines, chemokines, cyclooxygenase-2 (COX-2) 
and prostaglandins, which will trigger a cascade of 
similar signals in another inflammatory, stromal and 
tumor cells. The result is a broad inflammatory 
signature in the tumor microenvironment with 
consequent cell proliferation, transition of epithelial to 
mesenchymal cells, increase in blood and lymphatic 
vessel formation and inhibition of immune response 
[90] (Figure 3).  
Tumor-associated macrophages (TAMs), mast 
cells and T cells are important components of the 
inflamed tumor microenvironment. Macrophages are 
differentiated from monocytes recruited by 
tumor-derived chemokines and, depending on the 
activating signals, they exhibit pro- or 
anti-inflammatory effects, promoting or suppressing 
tumor activity. Macrophage referred to as M1 has a 
cytotoxic characteristic and can induce responses of 
helper T cells to pathogens. M2 macrophages secrete 
growth and angiogenic factors, release 
metalloproteases for wound healing and decrease 
inflammatory responses. [90]. Through the course of 
tumor initiation, macrophages have a central role in 
the immune response caused by chronic infection or 
irritation, producing cytokines that recruit other cells 
of the immune system. After this phase, the 




macrophages display a M2 phenotype that stimulates 
the neoplastic progression [91]. There are evidences 
that this second type of action occurs in response to 
macrophage colony-stimulating factor 1 (CSF-1) and 
interleukins present in the tumor microenvironment 
[92], with consequent production of growth factors 
and metalloproteases by macrophages, invasion and 
metastasis [93].  
The spread of metastases to specific anatomical 
sites also appears to be partly mediated by 
macrophages. Primary tumors secrete exosomes or 
soluble factors that attract macrophages to 
pre-metastatic niche and induce their 
reprogramming, for example by transferring 
oncoproteins through exosomes. The acquisition of a 
pro-vasculogenic phenotype boosts the development 
of a suitable microenvironment for tumor progression 
[94, 95].  
The discrepancy in the signals sent by tumor 
cells for macrophage activation could explain the 
contradictory prognosis observed in different tumors. 
For example, the presence of macrophages has been 
associated with reduced survival in breast carcinoma 
[96], while it is associated with favorable prognosis in 
colorectal cancer [97]. Analysis of proteins secreted by 
carcinoma cells that could influence macrophage 
phenotype identified the proteoglycan versican 
(VCAN) in colon carcinoma cell lines. Although the 
presence of stromal VCAN has not been associated 
with increased survival in colorectal cancer, its 
expression by epithelial cells in the periphery of the 
tumor was correlated with an improved prognosis 
suggesting that this factor is secreted by cancer cells 
and can participate in monocyte/macrophage 
differentiation [93].  
In addition to macrophages, other immune cells 
that modulate inflammatory responses play an 
important role in tumor progression. Among them are 
the neutrophils, which similarly to the macrophages 
may have both pro-tumoral and anti-tumoral effects 
[98]. Neutrophils are attracted in response to 
interleukin (IL-8) released by tumor cells and secrete 
nitric oxide, reactive oxygen species and matrix 
metalloproteinases [99]. Depending on the context, 
neutrophils can release elastase promoting cell 
proliferation [100] and epithelial-mesenchymal 
transition [101], or modulate tumor cell lysis via 
T-lymphocytes [102].  
Dendritic cells (DC) also play an important role 
in the regulation of inflammation, mainly due to their 
ability to secrete different cytokines and chemokines. 
DCs are able to initiate, expand and regulate the 
immune response. Although DCs may contribute to 
inhibit tumor development, neoplastic cells, in turn, 
can exploit DC to evade immunity [103]. The DC 
secretome profile is less rich than the cytoplasmic 
proteome, but has been showed to be more specific 
and sensitive to functional changes, indicating that it 
could be an interesting source of potential biomarkers 
involved in the regulation of inflammatory processes 
[104]. 
Recently, Seehawer and collaborators [105] 
showed that necroptosis, a pro-inflammatory type of 
cell death [106], is associated with a specific cytokine 
expression profile that apparently induce epigenetic 
alterations and affect the behavior of neighbor cells, 
similarly to what was observed by Ohanna et al (2011) 
[74] in senescent cells. The important observation of 
Seehawer et al. was that necropsis and apoptosis 
influence the fate of cells and the resultant cancer 
subtype. Therefore, inflammatory processes, no 
matter if triggered by microorganism infection or a 
type of cell death taking place in the 
microenvironment, are important contributors to 
tumorigenesis and even to cancer subtype 
specification. 
Secretome Components and 
Angiogenesis  
Angiogenesis is defined as the formation of new 
vessels from a pre-existing vascular network. The 
process is driven by the demand for oxygen, 
nutrients, and requires interactions between different 
cell types, the extracellular matrix and several 
cytokines and growth factors. Although fundamental 
in development, tissue maintenance and survival, 
angiogenesis plays a central role in tumor 
progression, invasion and metastasis [107]. 
Several conditions influence angiogenesis, 
including metabolic stress (hypoxia, acidosis, 
hypoglycemia), mechanical stress (compression 
generated by high cell proliferation), inflammatory 
responses (tumor-infiltrating immune cells) and 
genetic mutations (oncogene activation or inhibition 
of tumor suppressor genes) [108]. The major effectors 
of this process are regulators of growth factors, such 
as HIF1-alpha that drives vascular endothelial growth 
factor (VEGF) expression, activators of proliferation 
and migration of endothelial cells, such as growth 
factors that bind to the tyrosine kinase receptors 
(VEGF, FGF, PDGF, EGF), and lysophosphatidic acid 
(LPA) that interacts with G protein-coupled 
transmembrane receptors [109, 110]. Among the 
inhibitors are thrombospondin-1 and statins 
(angiostatin, endostatin, canstatin and tunstatina) 
[109]. These pro- and anti-angiogenic factors may be 
released by tumor cells or derived from the tumor 
microenvironment [109].  
Zhong and collaborators [111] studied the 
secretome of stromal cells during angiogenesis in a 




co-culture with lung cancer cells. They observed that 
the co-culturing promoted a secretome that increased 
migration of stromal cell, triggered endothelial tube 
formation, and induced cell proliferation. Secreted 
proteins included growth factors, interleukins, 
cytokines and chemokines, such as VEGF, IL-18, 
tumor necrosis factor (TNF-alpha), cytokine receptor 
common subunit beta (GM-CSF) and C-C motif 
chemokine 2 (MCP-1). Other studies have shown the 
involvement of additional secreted proteins in 
angiogenesis, such as IL-8 released by glioblastoma 
cells [112], cysteine-rich angiogenic inducer CYR61 
[113, 114] and hepatoma-derived growth factor 
(HDGF) [115] released by bone marrow stem cells and 
glioblastoma cells, respectively (Figure 3). 
As mentioned before, tumor cells secrete not 
only soluble factors, but also extracellular vesicles that 
promote migration, invasion, tube formation, and 
neovascularization in vivo [116]. Choi and 
collaborators [117] performed a comparative 
proteomic analysis of EVs and secretome in primary 
and metastatic colorectal cancer and detected many 
differences. The authors observed that EVs are 
enriched in plasma membrane, cytoskeletal and 
endosomal proteins, whereas secretome has proteins 
from extracellular matrix and extracellular region. 
The antigen CD276 (or B7-H3), which is an 
immunoregulator and cell surface tumor endothelial 
marker, showed a higher expression in EVs from 
metastatic cells. CD276 was already reported 
overexpressed during pathological but not 
physiological angiogenesis, as well as in tumor 
endothelial cells and in neoplastic cells [118], and 
positively correlated with microvessel density [119]. 
Other studies showed similar results, including 
exosomes released from glioma cells in hypoxia, a 
condition that is a potent inducer of angiogenesis in 
vivo and ex vivo [120]. Therefore, CD276 appear to be a 
promising target for antiangiogenic therapies. 
 
Figure 3. Cancer secretome, inflammation and angiogenesis. Gene mutations induce the expression of inflammation-related programs in neoplastic cells with activation 
of several transcription factors. The resulting signaling events induce immune cells to produce inflammatory mediators, including cytokines, chemokines, cyclooxygenase-2 
(COX-2) and prostaglandins, which will trigger a cascade of signals in inflammatory, stromal and tumor cells. Neutrophils can release matrix metalloproteinases (MMPs), nitric 
oxide (NO2), reactive oxygen species (ROS) and elastase, promoting cell proliferation and epithelial-mesenchymal transition (EMT). Neoplastic and immune cells can also secrete 
pro-angiogenic factors, including growth factors (VEGF, FGF, PDGF, EGF, HDGF), interleukins, cytokines and chemokines (IL-8, IL-18) and cysteine-rich angiogenic inducer 
CYR61. 
 




Another potential antiangiogenic target is 
RalA-binding protein 1 (or RalBP1), a 
multifunctional protein that contains binding sites for 
signaling effectors and is expressed in many human 
tissues and overexpressed in tumors. RalBP1 
modulates endothelial cell proliferation and 
migration by regulating the secretion of the 
angiogenic factor VEGF and the transcriptional 
activity of HIF-1 by the tumor [121, 122].  
Angiogenic inhibitors targeting VEGF have 
demonstrated therapeutic efficacy in multiple human 
cancers. However, the benefits of these therapies are, 
at best, temporary and are followed by resistance in 
most patients [123]. One explanation for this outcome 
is the involvement of alternate proangiogenic 
mediators [124], such as fibroblast growth factor 2 
(FGF-2), IL-8, placenta growth factor (PIGF) and 
pleiotrophin [125]. 
As previously mentioned, nonsteroidal 
anti-inflammatory drugs have been found to be 
effective in preventing cancer. Their main 
mechanisms of action are pro-apoptotic and 
anti-angiogenic inhibiting malignant transformation 
and suppressing proliferation [126]. One example is 
Sulindac, which is used to prevent colorectal cancer 
and reduces the secreted modulators of apoptosis and 
angiogenesis such as IL-8 [127].  
Approaches for Cancer Secretome Studies 
Secretome provides important information 
relevant to understanding the biology and behavior of 
cancer. Proteins of the cancer secretome have key 
roles in many biological processes and can be used in 
earlier diagnosis, disease monitoring as well as in 
therapy efficacy evaluation [128]. The approaches for 
secretome studies are dependent on the target and the 
sample type, and can vary widely, each of them with 
advantages and limitations. The two main sources of 
cancer secretome are biological fluids and cancer cell 
line supernatants. Biofluids, which directly reflect the 
conditions in vivo, and conditioned medium obtained 
from cell culture, allow to investigate nucleic acids, 
proteins, metabolites, lipids and carbohydrates by 
different methods of detection. 
Biofluids  
Serum and plasma are the most widely used 
biological fluids for clinical diagnosis, mainly due to 
their non-invasive characteristic of sample collection 
and because they represent a reservoir of molecules 
released by the tissues. Lin et al. [129] summarized the 
data from secretome studies using patient serum, 
plasma or tissue samples in breast, colorectal, gastric, 
liver, lung and prostate cancers, to provide a clinical 
validation of potential biomarkers and to determine 
their functional and diagnostic values. The authors 
emphasized that the characterization of 
serum/plasma biomarkers is not simple due to 
variations in concentration at relatively low levels, 
pre-analytical sequestration/degradation and clinical 
factors. In addition, blood contains multiple 
molecules secreted by different organs, as well as 
highly abundant proteins such as albumin and 
immunoglobulins that limits the detection of low 
abundance proteins [129].  
Several biofluids other than serum and plasma 
have also been analyzed, such as saliva [130], the 
interstitial fluid of tissues (IF) [131], nipple aspirate 
fluid [132], pleural effusion [133], bile, pancreatic and 
digestive juices[134], and ascites fluid[135],. They are 
promising sources of biomarkers in a less complex 
matrix when compared to plasma or serum. 
Haslene-Hox and collaborators [136] reviewed several 
techniques for the isolation of interstitial fluids, and 
observed a great variation in their composition, which 
seems to be dependent on the method of isolation. 
The authors also found that tumor interstitial fluid is 
hypoxic and acidic compared with subcutaneous fluid 
and plasma. In addition, concentrations gradients 
may indicate whether fluid components are locally 
synthesized or derived from plasma. However, an 
important question is the origin of many proteins, 
from extracellular space or from cellular leakage. 
Deciphering the overall biofluid composition 
and dynamics remains a major challenge. Despite the 
difficulties [2, 137], some methods have been applied 
for analyzing the secretome in vivo, such as 
microdialysis and ultrafiltration. The microdialysis 
method relies on the passive diffusion of substances 
across a semi-permeable membrane driven by a 
concentration gradient [18, 137]. However, peptide 
and protein recovery are still challenging because the 
dialysis efficiency is very low (~1%) as a consequence, 
for example, of the number of pores within the 
membrane. Therefore, the dialysate data may not 
correspond to the molecular size distribution and 
concentration of the biofluid [136]. The ultrafiltration 
technique also uses semi-permeable membranes to 
separate substances, but has some advantages when 
compared to microdialysis. The ultrafiltration uses 
negative pressure to collect a fluid and facilitates 
long-term and dynamic sampling collection, without 
changing the original concentration of the biofluid 
[18, 137]. 
Conditioned Medium  
Analyses of cell-conditioned medium (CM) have 
been widely performed to identify secreted proteins 
and cancer biomarkers, although cultures of 
neoplastic cells do not reconstitute tumor tissue and 




its microenvironment [3, 17]. Tumor tissues may also 
exhibit dissimilar levels or even absence/presence of 
metabolites and proteins compared with standard 
culture medium [61]. Nevertheless, the secretome 
released in the culture medium is less complex than 
biofluids and facilitates the identification of low 
abundance proteins. It also comprises a good option 
to assess the concentration of released molecules and 
provides information about biological processes [2, 
18, 129]. 
The discovery of biomarkers in CM also has its 
technological challenges similar to what is observed 
in biofluids. For example, secreted proteins in CM are 
often masked by proteins present in supplements 
added to the culture medium. To circumvent this 
limitation, cells are usually incubated in serum-free 
medium experiments to reduce interference from 
serum components. Nevertheless, the serum 
deprivation may result in altered metabolism, 
decreased proliferation, increased cell death and 
protein release by autolysis, as well as in abnormal 
protein synthesis and secretion [129]. To minimize the 
effect of in vitro conditions, isotope-labeled amino 
acids can be introduced into the culture medium 
enabling the differentiation between serum proteins 
and secreted proteins [129, 138, 139]. Furthermore, the 
optimization of incubation time and cellular 
confluence appears to reduce contamination with 
intracellular proteins [140].  
Using a dataset from five cell lines, Méndez and 
Villanueva [141] showed that many proteins in CM 
were both extra and intracellular according to Gene 
Ontology classification. However, several of them 
were solely intracellular, meaning that they are 
indeed derived from cell death and apoptosis under 
serum starvation or may be secreted by non-classical 
pathways, such as exosomes. 
To validate Méndez and Villanueva results, we 
assembled data retrieved from the Human Cancer 
Secretome Database (HCSD) [142] 
(http://www.cancersecretome.org) and a subset of 
proteins identified after a literature search in PubMed 
database (Table S1 and Table S2, respectively). Genes 
encoding for these proteins were included in the 
dataset as follows: (a) 1,835 non-redundant genes 
(log2 fold change values below 1 or above 1) from 9 
high-throughput studies available in HCSD on seven 
cancer types (colorectal, esophageal, gastric, 
glioblastoma, head and neck, lung, pancreatic 
cancers) using 35 human neoplastic and 3 human 
non-neoplastic cell lines, and (b) 37 non-redundant 
genes from the literature search (references in Table  
S1 and Table S2, respectively). Following manual 
curation and re-evaluation of redundancy, a final list 
of 1,776 genes was obtained. A gene ontology and 
pathway search using DAVID tools [143] showed a 
total of 1,767 DAVID identifiers. The most 
overrepresented cellular component category was 
extracellular exosome (Bonferroni corrected 
p-values=1.35-292), followed by cytosol, focal adhesion, 
extracellular matrix and space, cell-cell adherens 
junction, membrane and cytoplasm categories (Table 
S3, sheet 1 - cellular component), suggesting that 
many proteins may be located in both extra and 
intracellular compartments, or are derived from cell 
death/apoptosis processes, as shown by Méndez and 
Villanueva [141]. DAVID analysis also identified 
significantly enriched biological processes and 
pathways related to cell-cell adhesion, extracellular 
matrix organization, ECM-receptor interaction, and 
focal adhesion, although processes and pathways 
associated with intracellular proteins have also been 
observed (Table S3, sheet 2 – biological processes, 
sheet 3 - pathways). In addition, more than 290 
annotation clusters were obtained, 13 of them with 
enrichment scores>5.0 (Table S4). The results showed 
overrepresented clusters related to cell-cell adhesion, 
translation, protein metabolism, and secretion, again 
showing processes relevant to crosstalk between cells 
and to intracellular pathways. 
The results address a question as to why many 
intracellular proteins are present in the secretome. Are 
they only a consequence of cell culture conditions or 
may be important in modulating cell communication 
and local or distant biological processes? As 
commented before, senescence, necropsis and 
apoptosis may not be an end in itself, but generate 
signals that stimulate cells in the neighborhood or in 
different tissues and organs. More studies are 
therefore necessary to sort the wheat from the chaff 
and answer these questions.  
Complementary Methodologies 
Several complementary methodologies have 
been applied in secretome studies of both biofluids 
and CM, such as microarrays and large-scale cDNA 
sequencing to analyze transcripts present in exosomes 
[144], liquid chromatography-mass spectrometry and 
antibodies for targeted capture and detection of 
secreted proteins [17], and mass spectrometry and 
nuclear magnetic resonance to identify metabolites 
[145]. Using these methodologies, many data on the 
cancer secretome have been generated and validated 
in a high number of samples and/or patients. For 
example, the study performed by Aleckovic and 
collaborators, using a quantitative mass 
spectrometry-based proteomics approach, identified 
hundreds of breast cancer- and melanoma-derived 
proteins secreted from lung metastatic cells. The 
authors observed that Nidogen-1 (NID-1), a basement 




membrane glycoprotein with binding sites for other 
ECM molecules, promote lung metastasis of breast 
cancer and melanoma and induces prometastatic 
characteristics, and its expression is correlated with 
poor prognosis [146]. Likewise, Pierredon et al. [147] 
while investigating the secretome of ovarian cancer by 
mass spectrometry identified gelsolin, a protein 
involved in cell motility, phagocytosis, apoptosis, 
platelet formation, and activation, with significantly 
lower expression levels in cancer cells and in the sera 
of ovarian cancer patients.  
Data on cancer secretome have also been 
organized in database formats. For example, The 
Human Cancer Secretome Database [142], mentioned 
above, contains 7000 nonredundant human proteins 
collected from up to 35 high-throughput studies on 17 
cancer types. The repository of cancer-associated 
peptidomes in human biofluids (CancerPDF) [148] 
(http://crdd.osdd.net/raghava/cancerpdf/) covers 
nearly 30 types of human cancers and contains 14,367 
experimentally validated peptides. The 2004 release of 
the web-based Secreted Protein Database (SPD) [149] 
(https://www.hsls.pitt.edu/obrc/index.php?page=
URL1104935692) contains a total of 18152 secreted 
proteins in Human, Mouse and Rat proteomes. The 
Plasma Proteome Database [150] 
(http://www.plasmaproteomedatabase.org/) hosts 
qualitative and quantitative information on proteins 
from plasma and serum and the ones reported in 
extracellular vesicle isolated from plasma. The 
PeptideAtlas [151] (http://www.peptideatlas.org/) 
provides data on human plasma and urine and The 
Human Metabolome Database [152] 
(http://www.hmdb.ca/) contains information about 
metabolites in different biospecimens. Unfortunately, 
not all databases are regularly updated. 
Although with restrictions related to false 
positive and false negative assignments [144], 
bioinformatic tools have contributed significantly not 
only to organize information but also to characterize 
the secretome. For example, the SignalP software 
[153] (http://www.cbs.dtu.dk/services/SignalP/) 
predicts the presence of signal peptide cleavage sites 
located at the N-terminus of proteins secreted by the 
classical pathway. Proteins secreted by the non- 
classical pathway are devoid of a signal peptide and 
can be predicted by the SecretomeP software [154]  
(http://www.cbs.dtu.dk/services/SecretomeP/) 
through the sequence features, such as 
posttranslational modifications, size, and charge. 
Clustering of expression profiles and functional 
analyses of secretome may also reveal signatures of 
cancer cells [155]. In this respect, ExoCarta [156] 
(www.exocarta.org) and Gene Ontology consortium 
[157, 158] (www.geneontology.org) databases 
facilitate the access to information about content of 
exosomes, and cell location, molecular function and 
biological process of proteins, and help to distinguish 
between the true secreted proteins and intracellular 
contaminants. 
Conclusion 
The secretome is a rich reservoir for cancer 
biomarkers. Decoding the secretome in the tumor 
microenvironment and understanding how it enables 
the exchange of signals between tumor cells and 
stromal cells could help to elucidate the biochemical 
pathways involved in tumorigenesis, from early to 
advanced stages, and to identify potential biomarkers 
for the development of new diagnostic and prognostic 
tools, therapies and prediction of therapeutic 
responses.  
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